Dermitop Cream 20gm

INTRODUCTION

DERMITOP contains mometasone which belongs to the group of medicines called topical corticosteroids. It is used to reduce itchiness and redness caused by certain skin problems such as psoriasis and atopic eczema (atopic dermatitis) in adults and children aged 2 years and above. Psoriasis is an auto-immune skin disorder, in which itchy, scaly, pink patches develop on the knees, elbows, scalp and other parts of the body. Atopic eczema is a condition in which, itchy, red or brown patches develops on the skin due to external agents e.g. detergents.

Mometasone inhibits the production of inflammatory mediators like prostaglandins and leukotrienes and decrease the number of epidermal mitoses, reduce apoptosis and enhance neutrophils survival in the affected skin cells. If you feel your skin become irritated or sensitive after using this medicine, inform your doctor immediately. Do not use this medicine on your face for more than recommended duration. Treated areas on the face should not be covered with a plaster or bandage. Avoid applying this medicine around your eyes, including eyelids. Before applying this medicine, inform your doctor if you have any other skin disorders like rosacea, acne, ulcerated skin or perianal and genital itching. Contact your doctor before using this medicine if you are pregnant or breastfeeding.

USES OF DERMITOP

• Treats psoriasis and atopic dermatitis in adults and children aged 2 years and above

HOW DERMITOP WORKS

Mometasone has anti-inflammatory, antipruritic and vasoconstrictive properties. It inhibits the biosynthesis of prostaglandins and leukotrienes (potent mediators of inflammation) by inhibiting the release of their common precursor arachidonic acid.

Additionally, it inhibits the expression of phospholipase A2 and proinflammatory genes such as interleukin-1 alpha, nuclear factor-kappa-B and tumor necrosis factor (TNF), which significantly reduces apoptosis and relieves the skin from inflammation and itching. 

DIRECTIONS FOR USE

Always apply this medicine as directed by your physician. It is for external use only. Apply a thin layer of this medicine on the affected area once daily. Treated areas on the face should not be covered with a plaster or bandage. Do not use this medicine on your face for more than 5 days. Avoid applying this medicine around your eyes, including eyelids.

SIDE EFFECTS OF DERMITOP

HOW TO MANAGE SIDE EFFECTS

Skin irritation:

Avoid hot showers because hot water can irritate the skin. Do not rub or scratch the affected area. Do not use perfumed soaps or deodorants. Avoid excessive sun exposure. Always use sunscreen and protective clothing when outdoors. Use moisturizers regularly to soothe and hydrate the affected area. If it does not get better within a week, speak to a doctor.

Excessive hair growth:

Consult your doctor as they may be able to help you by reducing your dose or by prescribing an alternate medicine. If you are bothered by this, do these at home to remove or lighten the hair such as waxing, shaving or using hair removal creams.

WARNING & PRECAUTIONS

INTERACTIONS

Tell your doctor if you are using, have recently used or might use any other topical medicines.

SYNOPSIS

MORE INFORMATION

Store below 20-25°C and keep out of reach of children.

FAQs ABOUT DERMITOP

Can DERMITOP be used in children?

Yes. It can be used in children aged 2 years and above. It is strictly not recommended for use in children aged below 2 years. Consult your doctor for advice.

Can DERMITOP be used on face?

Yes. This medicine can be applied on face on the advice of your physician. Avoid applying this medicine around your eyes, including eyelids.

REFERENCES

1. KD. Tripathi. Drugs acting on skin and mucous membranes. Essentials of medical pharmacology. Seventh edition. 2013. Page – 895-896.

2. Bernard P. Schimmer and John W. Funder. ACTH, Adrenal Steroids, and Pharmacology of the Adrenal Cortex. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1226.

3. Gerald G. Briggs and Roger K. Freeman. M. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 2626-2628.

4. Azidus Brasil. Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared with Mometasone Furoate (Psoriasis). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on October 2010] [Accessed 26th November 2020] https://clinicaltrials.gov/ct2/show/NCT01228656

5. Yao Liao. Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on March 2016] [Accessed 26th November 2020] https://clinicaltrials.gov/ct2/show/NCT02495064

6. Fabrizio Spada, Tanya M Barnes, and Kerryn A Greive. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. NCBI; PMC US National Library of Medicine, National Institute of Health. February 2018. [Accessed 26th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099284/

7. Glenmark Pharmaceuticals s.r.o., Accord Healthcare Limited and Glenmark Pharmaceuticals Europe Limited. Electronic Medicines Compendium (EMC); [Revised on July 2017] [Accessed 26th November 2020] https://www.medicines.org.uk/emc/files/pil.9994.pdf

8. Schering-Plough Labo NV. Electronic Medicines Compendium (EMC); [Revised on June 2019] [Accessed 26th November 2020] https://www.medicines.org.uk/emc/files/pil.79.pdf

9. Tiofarma B.V. Electronic Medicines Compendium (EMC); [Revised on June 2020] [Accessed 26th November 2020] https://www.medicines.org.uk/emc/files/pil.5042.pdf

10. Gerard Laboratories, Generics [UK] Limited and Mylan UK Healthcare Limited. Electronic Medicines Compendium (EMC); [Revised on May 2020] [Accessed 26th November 2020] https://www.medicines.org.uk/emc/files/pil.8168.pdf

11. Schering Plough Canada, Inc. U.S. Food & Drug Administration; [Revised on March 2013] [Accessed 26th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf